This study tests a new medicine called **IMVT-1402** for a skin disease called **Cutaneous Lupus Erythematosus (CLE)**. CLE is a condition where the immune system attacks the skin, causing it to become inflamed. The study has three parts over **67 weeks**. In **Period 1**, participants get either the IMVT-1402 or a placebo (a fake treatment) for **12 weeks**. Then, in **Period 2**, everyone gets the IMVT-1402 for **14 weeks**. Finally, in **Period 3**, participants are randomly given either a higher or lower dose of IMVT-1402 for **26 weeks**.

• **Total study duration**: Up to 67 weeks (including screening, treatment, and follow-up).
• **Visits**: Regular visits for treatment and check-ups over the study period.
• **Eligibility**: Participants must have specific markers of CLE and not have certain other conditions.

To join, you need a confirmed CLE diagnosis. The study does not allow people with certain other health issues. Remember, there may be risks, so discuss with your doctor before participating.